board of consultants

Article

Robert P. Blereau, MD Family Medicine, Morgan City, LouisianaMichael S. Heitler, MD Clinical Professor of Pediatrics, New York University School of Medicine, New YorkDavid L. Kaplan, MD Clinical Assistant Professor of Dermatology, University of Missouri Kansas City School of Medicine, Overland Park, KansasJoseph A. Lieberman III, MD, MPH Professor of Family Medicine, Jefferson Medical College, Philadelphia

Robert P. Blereau, MD
Family Medicine, Morgan City, Louisiana

Michael S. Heitler, MD
Clinical Professor of Pediatrics, New York University School of Medicine, New York

David L. Kaplan, MD
Clinical Assistant Professor of Dermatology, University of Missouri Kansas City School of Medicine, Overland Park, Kansas

Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine, Jefferson Medical College, Philadelphia

Recent Videos
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Discussion: AAP's opioid for acute pain clinical practice guideline with Jessica Spruit, DNP
Bobbie Monaco, MSN, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
New blood test predicts preterm birth risk early in pregnancy | Image Credit: © angellodeco - © angellodeco - stock.adobe.com.

New blood test predicts preterm birth risk early in pregnancy

Celeste Krewson, Assistant Editor
April 21st 2025
Article

A new study found that cell-free DNA from routine prenatal testing can accurately identify preterm birth risk without added cost or procedures.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Weekly review: FDA approves dupilumab, ACIP meets, and more | Image Credit: © Artur - © Artur - stock.adobe.com.

Weekly review: FDA approves dupilumab, ACIP meets, and more

Joshua Fitch, Senior Editor
April 21st 2025
Article

From the FDA approvals of dupilumab and maralixibat tablets to a new puzzler case study, get caught up with our weekly review article.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Krystina Way, MEd, BCBA, LBA, clinical assessment specialist, BlueSprig.

The crucial role pediatricians play in early autism diagnosis and why it matters

Krystina Way, MEd, BCBA, LBA
April 18th 2025
Article

Find out how pediatricians play a crucial role in early autism diagnosis and how to advise families post-diagnosis.

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

Joshua Fitch, Senior Editor
April 18th 2025
Article

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

© 2025 MJH Life Sciences

All rights reserved.